{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:35:44Z","timestamp":1790678144869,"version":"4.1.0"},"reference-count":62,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The concept of liver fibrosis and cirrhosis being static and therefore irreversible is outdated. Indeed, both human and animal studies have shown that fibrogenesis is a dynamic and potentially reversible process that can be modulated either by stopping its progression and\/or by promoting its resolution. Therefore, the study of the molecular mechanisms involved in the pathogenesis of liver fibrosis is critical for the development of future antifibrotic therapies. The fibrogenesis process, common to all forms of liver injury, is characterized by the increased deposition of extracellular matrix components (EMCs), including collagen, proteoglycans, and glycoproteins (laminin and fibronectin 2). These changes in the composition of the extracellular matrix components alter their interaction with cell adhesion molecules, influencing the modulation of cell functions (growth, migration, and gene expression). Hepatic stellate cells and Kupffer cells (liver macrophages) are the key fibrogenic effectors. The antifibrogenic mechanism starts with the activation of Ly6Chigh macrophages, which can differentiate into macrophages with antifibrogenic action. The research of biochemical changes affecting fibrosis irreversibility has identified lysyl oxidase-like 2 (LOXL2), an enzyme that promotes the network of collagen fibers of the extracellular matrix. LOXL2 inhibition can decrease cell numbers, proliferation, colony formations, and cell growth, and it can induce cell cycle arrest and increase apoptosis. The development of a new humanized IgG4 monoclonal antibody against LOXL2 could open the window of a new antifibrogenic treatment. The current therapeutic target in patients with liver cirrhosis should focus (after the eradication of the causal agent) on the development of new antifibrogenic drugs. The development of these drugs must meet three premises: Patient safety, in non-cirrhotic phases, down-staging or at least stabilization and slowing the progression to cirrhosis must be achieved; whereas in the cirrhotic stage, the objective should be to reduce fibrosis and portal pressure.<\/jats:p>","DOI":"10.3390\/ijms20071634","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T03:39:28Z","timestamp":1554262768000},"page":"1634","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["LOXL2\u2014A New Target in Antifibrogenic Therapy?"],"prefix":"10.3390","volume":"20","author":[{"given":"Angela","family":"Puente","sequence":"first","affiliation":[{"name":"Digestive Disease Department, Marqu\u00e9s de Valdecilla University Hospital, Cantabria University, 39008 Santander, Spain"},{"name":"Health Research Institute Marques de Valdecilla (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Ignacio","family":"Fortea","sequence":"additional","affiliation":[{"name":"Digestive Disease Department, Marqu\u00e9s de Valdecilla University Hospital, Cantabria University, 39008 Santander, Spain"},{"name":"Health Research Institute Marques de Valdecilla (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0012-484X","authenticated-orcid":false,"given":"Joaquin","family":"Cabezas","sequence":"additional","affiliation":[{"name":"Digestive Disease Department, Marqu\u00e9s de Valdecilla University Hospital, Cantabria University, 39008 Santander, Spain"},{"name":"Health Research Institute Marques de Valdecilla (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Arias Loste","sequence":"additional","affiliation":[{"name":"Digestive Disease Department, Marqu\u00e9s de Valdecilla University Hospital, Cantabria University, 39008 Santander, Spain"},{"name":"Health Research Institute Marques de Valdecilla (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Iruzubieta","sequence":"additional","affiliation":[{"name":"Digestive Disease Department, Marqu\u00e9s de Valdecilla University Hospital, Cantabria University, 39008 Santander, Spain"},{"name":"Health Research Institute Marques de Valdecilla (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Llerena","sequence":"additional","affiliation":[{"name":"Digestive Disease Department, Marqu\u00e9s de Valdecilla University Hospital, Cantabria University, 39008 Santander, Spain"},{"name":"Health Research Institute Marques de Valdecilla (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Huelin","sequence":"additional","affiliation":[{"name":"Digestive Disease Department, Marqu\u00e9s de Valdecilla University Hospital, Cantabria University, 39008 Santander, Spain"},{"name":"Health Research Institute Marques de Valdecilla (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"F\u00e1brega","sequence":"additional","affiliation":[{"name":"Digestive Disease Department, Marqu\u00e9s de Valdecilla University Hospital, Cantabria University, 39008 Santander, Spain"},{"name":"Health Research Institute Marques de Valdecilla (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Crespo","sequence":"additional","affiliation":[{"name":"Digestive Disease Department, Marqu\u00e9s de Valdecilla University Hospital, Cantabria University, 39008 Santander, Spain"},{"name":"Health Research Institute Marques de Valdecilla (IDIVAL), 39008 Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","article-title":"Pathobiology of liver fibrosis: A translational success story","volume":"64","author":"Lee","year":"2015","journal-title":"Gut"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies","volume":"44","author":"Pagliaro","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cgh.2013.01.005","article-title":"Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies","volume":"11","author":"Rockey","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","article-title":"Pathogenesis of liver fibrosis","volume":"6","author":"Friedman","year":"2011","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nri3623","article-title":"Liver fibrosis and repair: Immune regulation of wound healing in a solid organ","volume":"14","author":"Pellicoro","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: Concept to treatment","volume":"62","author":"Trautwein","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/nm1663","article-title":"TLR4 enhances TGF-beta signaling and hepatic fibrosis","volume":"13","author":"Seki","year":"2007","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.2353\/ajpath.2007.060887","article-title":"Proangiogenic Cytokines as Hypoxia-Dependent Factors Stimulating Migration of Human Hepatic Stellate Cells","volume":"170","author":"Novo","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2013.12.025","article-title":"Macrophage heterogeneity in liver injury and fibrosis","volume":"60","author":"Tacke","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","article-title":"Angiogenesis in liver disease","volume":"50","author":"Fernandez","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1172\/JCI66028","article-title":"Evolving therapies for liver fibrosis","volume":"123","author":"Schuppan","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrgastro.2010.97","article-title":"Evolving challenges in hepatic fibrosis","volume":"7","author":"Friedman","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.ajpath.2012.02.004","article-title":"Recent developments in myofibroblast biology paradigms for connective tissue remodeling","volume":"180","author":"Hinz","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/hep.23405","article-title":"Portal fibroblasts: Underappreciated mediators of biliary fibrosis","volume":"51","author":"Dranoff","year":"2010","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/jhep.2003.50044","article-title":"Vascular mediators in the injured liver","volume":"37","author":"Rockey","year":"2003","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","article-title":"Liver sinusoidal endothelial cells: Physiology and role in liver diseases","volume":"66","author":"Poisson","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_18","first-page":"G723","article-title":"Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages","volume":"300","author":"Barron","year":"2011","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1053\/j.gastro.2012.05.049","article-title":"Interleukin-17 signaling in inflammatory, kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice","volume":"143","author":"Meng","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1084\/jem.20092121","article-title":"Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent","volume":"207","author":"Wilson","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1053\/j.gastro.2012.07.031","article-title":"Th17 Cells Regulate Liver Fibrosis by Targeting Multiple Cell Types: Many Birds With One Stone","volume":"143","author":"Gao","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00281-009-0169-0","article-title":"Mononuclear cells in liver fibrosis","volume":"31","author":"Marra","year":"2009","journal-title":"Semin. Immunopathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/gutjnl-2011-300304","article-title":"Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury","volume":"61","author":"Baeck","year":"2012","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","article-title":"Roles for Chemokines in Liver Disease","volume":"147","author":"Marra","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"E3186","DOI":"10.1073\/pnas.1119964109","article-title":"Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis","volume":"109","author":"Ramachandran","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(01)00260-4","article-title":"Hepatic stellate cell\/myofibroblast subpopulations in fibrotic human and rat livers","volume":"36","author":"Cassiman","year":"2002","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease","volume":"351","author":"Liaw","year":"2004","journal-title":"New Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis","volume":"308","author":"Veldt","year":"2012","journal-title":"JAMA"},{"key":"ref_29","first-page":"218A","article-title":"Impact of SVR in the development of all complications and fibrosis regression in a cohort of patients treated with interferon-base Triple Therapy and Direct Acting Antiviral","volume":"66","author":"Cabezas","year":"2017","journal-title":"Hepatology"},{"key":"ref_30","first-page":"17","article-title":"Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy","volume":"109","author":"Puente","year":"2017","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2013.03.013","article-title":"The diagnostic accuracy of Fibroscan\u00ae for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response","volume":"59","author":"Aghemo","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_33","first-page":"G25","article-title":"Assessment of liver fibrosis progression and regression by a serological collagen turnover profile","volume":"316","author":"Karsdal","year":"2019","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1053\/j.gastro.2004.03.009","article-title":"Spontaneous recovery from micronodular cirrhosis: Evidence for incomplete resolution associated with matrix cross-linking\u2606","volume":"126","author":"Issa","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10568","DOI":"10.1038\/srep10568","article-title":"Origin and evolution of lysyl oxidases","volume":"5","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1007\/s00018-006-6149-9","article-title":"Lysyl oxidase: An oxidative enzyme and effector of cell function","volume":"63","author":"Lucero","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1042\/CS20170175","article-title":"Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease","volume":"131","author":"Dongiovanni","year":"2017","journal-title":"Clin. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/hep.27320","article-title":"Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma","volume":"60","author":"Wong","year":"2014","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nature04695","article-title":"Lysyl oxidase is essential for hypoxia-induced metastasis","volume":"440","author":"Erler","year":"2006","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00141013","article-title":"Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression","volume":"43","author":"Chien","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_41","first-page":"120A","article-title":"Correlation between noninvasive markers of fibrosis and the hepatic venous pressure gradient (HVPG) in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH)","volume":"62","author":"Bosch","year":"2015","journal-title":"Hepatology"},{"key":"ref_42","first-page":"121A","article-title":"Serum lysyl oxidase-like-2 (sLOXL2) is correlated with the hepatic venous pressure gradient (HVPG) in patients with cirrhosis due to hepatitis C","volume":"62","author":"Afdha","year":"2015","journal-title":"Hepatology"},{"key":"ref_43","first-page":"123A","article-title":"Changes in liver stiffness by transient elastography (TE) and serum lysyl oxidase-like-2 (sLOXL2) in patients with cirrhosis treated with ledipasvir\/sofosbuvir (LDV\/SOF)-based therapy","volume":"62","author":"Bourliere","year":"2015","journal-title":"Hepatology"},{"key":"ref_44","first-page":"123","article-title":"Influence of the metabolic syndrome on fibrosis regression regulated by LOXL2 after sustained virologycal response","volume":"42","author":"Puente","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.2208","article-title":"Allosteric inhibition of lysyl oxidase\u2013like-2 impedes the development of a pathologic microenvironment","volume":"16","author":"Spangler","year":"2010","journal-title":"Nat. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/gutjnl-2016-312473","article-title":"Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal","volume":"66","author":"Ikenaga","year":"2017","journal-title":"Gut"},{"key":"ref_47","first-page":"22","article-title":"Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: A randomised, double-blind, controlled, phase 2 trial","volume":"5","author":"Raghu","year":"2017","journal-title":"Respir. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"243-e23","DOI":"10.1634\/theoncologist.2016-0479","article-title":"A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma","volume":"22","author":"Hecht","year":"2017","journal-title":"Oncologist"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"241-e15","DOI":"10.1634\/theoncologist.2017-0024","article-title":"A Phase II Randomized. Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma","volume":"22","author":"Benson","year":"2017","journal-title":"Oncologist"},{"key":"ref_50","first-page":"S409","article-title":"Simtuzumab, an antifibrotic monoclonal antibody against lysyl oxidase like 2, appears safe and well tolerated in patients with liver disease of diverse etiology","volume":"58","author":"Tatal","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"GS-US-384-1497 Investigators. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/hep.30199","article-title":"Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension","volume":"69","author":"Fuchs","year":"2019","journal-title":"Hepatology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1053\/j.gastro.2012.02.017","article-title":"Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C","volume":"142","author":"Castera","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2015). EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol., 63, 237\u2013264.","DOI":"10.1016\/j.jhep.2015.04.006"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jhep.2014.12.007","article-title":"Real-time shear-wave elastography: Applicability, reliability and accuracy for clinically significant portal hypertension","volume":"62","author":"Procopet","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2013.12.016","article-title":"Role of magnetic resonance elastography in compensated and decompensated liver disease","volume":"60","author":"Asrani","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2013.09.002","article-title":"Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease","volume":"60","author":"Banerjee","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2013.06.026","article-title":"Molecular MRI of Collagen to Diagnose and Stage Liver Fibrosis","volume":"59","author":"Fuchs","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_61","first-page":"716","article-title":"A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT","volume":"15","author":"Lalazar","year":"2008","journal-title":"J. Hepat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/liv.13268","article-title":"Potential use of metabolic breath tests to assess liver disease and prognosis: Has the time arrived for routine use in the clinic?","volume":"37","author":"Stravitz","year":"2016","journal-title":"Liver Int."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/7\/1634\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:42:16Z","timestamp":1760186536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/7\/1634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":62,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["ijms20071634"],"URL":"https:\/\/doi.org\/10.3390\/ijms20071634","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,2]]}}}